Clinical Trial Supply Market (2026-2031) - Growth Driven By Increasing Clinical Trial Activity
Dublin, Aug. 28, 2026 (GLOBE NEWSWIRE) -- The "Clinical Trial Supply - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Clinical Trial Supply Market to Reach USD 6.73 Billion by 2031, Driven by Multicountry Studies and Decentralized Trial Logistics
The global clinical trial supply market was valued at USD 4.31 billion in 2025 and is projected to increase from USD 4.60 billion in 2026 to USD 6.73 billion by 2031. The market is expected to register a compound annual growth rate of 7.92% during the 2026-2031 forecast period, supported by expanding Phase II and Phase III trial activity, increasingly complex global supply chains, and growing demand for direct-to-patient delivery services.
Multicountry Clinical Trials Strengthen Market Demand
The rising volume of Phase III multicountry trials is creating significant opportunities across the clinical trial supply market. Final U.S. Food and Drug Administration guidance on electronic common technical document submissions, issued in January 2025, reduced duplicate paperwork and shortened review cycles by approximately 15%. Sponsors are increasingly consolidating packaging and labeling operations in regional hubs while using cloud-based randomization and trial supply management platforms to maintain inventory visibility.
Oncology and rare-disease studies frequently operate across more than 20 countries, increasing demand for logistics providers with expertise in cross-border comparator sourcing, regulatory compliance, and temperature-controlled transportation. The European Medicines Agency's Clinical Trials Information System also enables a single application to cover all 27 European Union member states, supporting larger trial networks and harmonized quality processes.
Direct-to-Patient Logistics Accelerate Decentralized Trials
Decentralized clinical trial models are reshaping supply strategies. FDA guidance issued in May 2024 endorsed home delivery of investigational products under strict risk controls, accelerating the adoption of direct-to-patient logistics. Sponsors have reported faster enrollment and lower screen-failure rates when patient travel requirements are reduced, potentially supporting earlier regulatory submissions and commercialization.
Clinical trial couriers are expanding ambient, refrigerated, and frozen delivery capabilities with GPS monitoring, electronic proof of delivery, and secure digital audit trails. Adoption is particularly strong in cardiovascular, respiratory, and central nervous system studies involving treatments suitable for home administration. Consequently, specialized last-mile delivery is becoming a high-value clinical trial supply service.
Regulatory Divergence Raises Compliance Costs
Cross-border regulatory differences continue to place pressure on operating margins and trial timelines. China's National Medical Products Administration began pre-approval audits of overseas packaging facilities in June 2024, adding an estimated eight to 12 weeks to some study start-up schedules. Brazil introduced requirements in March 2025 for locally formulated comparators, requiring some sponsors to maintain duplicate supply chains.
Compliance costs for a 15-country Phase III trial increased by 19% between 2022 and 2025, according to a multi-sponsor survey. Multiple labeling formats, local comparator requirements, and additional quality-control testing are increasing demand for experienced supply partners while adding complexity to international studies.
Other influential clinical trial supply market trends include:
- Growth in temperature-sensitive biologics and advanced therapy medicinal product pipelines Adoption of AI-driven demand forecasting to reduce excess inventory and product waste Persistent temperature-excursion risks in emerging clinical trial markets
Manufacturing and Phase II Trials Offer Strong Growth Potential
Logistics and distribution accounted for 29.65% of market revenue in 2025, reflecting the essential role of global transportation and depot networks. Manufacturing is forecast to outpace the broader market with a 9.32% CAGR through 2031 as sponsors increasingly rely on contract development and manufacturing organizations for fill-finish operations, lyophilization, comparator procurement, and specialized production.
Packaging, labeling, and blinding services remain critical for double-blind cardiovascular and central nervous system studies. Automation is helping providers shorten release cycles, while AI-supported forecasting is reducing overage and improving inventory allocation. One European case study reported a 22% inventory reduction in 2025 following the implementation of advanced forecasting tools.
Phase III trials represented 41.24% of market value in 2025 due to their large patient populations, extended durations, and international reach. However, Phase II is projected to record the fastest growth, with a 10.72% CAGR through 2031. Adaptive study designs, multiple oncology dose levels, mid-study transfers between trial arms, and higher SKU counts are increasing the need for flexible depots, real-time inventory tracking, and rapid resupply capabilities.
Regional Clinical Trial Supply Market Outlook
North America generated 35.77% of global revenue in 2025, supported by mature depot infrastructure, extensive clinical site networks, and early adoption of decentralized trials. Increased near-shoring is also influencing regional operations, with some U.S. sponsors transferring packaging activities to Mexico. At the same time, shortages of skilled packaging and quality-assurance personnel are encouraging investment in automation.
Asia-Pacific is forecast to achieve the fastest regional growth, registering a 9.44% CAGR through 2031. China's conditional approval pathway, India's expanding base of GMP-certified facilities, and Japan's alignment with international electronic submission standards are attracting additional late-stage studies. South Korea and Australia are also gaining cardiovascular and metabolic trials through funding incentives, although cold-chain infrastructure gaps remain a challenge in parts of Southeast Asia.
Europe continues to benefit from centralized clinical trial applications and strong capabilities in cardiovascular, respiratory, and oncology research. Spain and Italy are attracting studies with competitive per-patient costs, while Germany, France, and the United Kingdom remain important locations for complex protocols. Emerging temperature-controlled logistics hubs in Dubai and Riyadh are strengthening the Middle East's role, while Brazil and Argentina continue to attract large Phase III programs despite comparator-sourcing and regulatory challenges.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Volume of Phase III Multicountry Trials
4.2.2 Expansion of Decentralized & Direct-To-Patient Logistics Models
4.2.3 Growth in Temperature-Sensitive Biologics & ATMP Pipelines
4.2.4 AI-Driven Demand Forecasting Reducing Overage & Waste
4.2.5 Tariff-Driven Near-Shoring of Packaging and Depot Networks
4.2.6 Sustainability & ESG Mandates Driving Adoption of Reusable, Low-Carbon Packaging
4.3 Market Restraints
4.3.1 Rising Cross-Border Regulatory Divergence Inflating Compliance Costs
4.3.2 Persistent Temperature-Excursion Losses in Emerging Markets
4.3.3 Skilled-Labor Shortages in GMP Packaging & QA Functions
4.3.4 Cyber-Security Risks to IRT / RTSM Platforms
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value in USD)
5.1 By Service
5.1.1 Logistics & Distribution
5.1.2 Storage & Retention
5.1.3 Packaging, Labelling & Blinding
5.1.4 Manufacturing
5.1.5 Comparator Sourcing
5.1.6 Supply-Chain Management / Forecasting
5.2 By Phase
5.2.1 Bioavailability / Bioequivalence
5.2.2 Phase I
5.2.3 Phase II
5.2.4 Phase III
5.2.5 Phase IV / Post-Marketing
5.3 By Therapeutic Area
5.3.1 Cardiovascular Diseases
5.3.2 Oncology
5.3.3 Respiratory Diseases
5.3.4 CNS & Mental Disorders
5.3.5 Infectious Diseases
5.3.6 Rare & Orphan Disorders
5.4 By End User
5.4.1 Pharmaceutical Companies
5.4.2 Biologics / Biotech Companies
5.4.3 Contract Research Organisations (CROs & CDMOs)
5.4.4 Medical-Device Companies
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 France
5.5.2.3 United Kingdom
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Almac Group
6.3.2 Biocair International
6.3.3 Catalent Inc.
6.3.4 DHL Global Forwarding / Life Sciences
6.3.5 Eurofins Scientific
6.3.6 FedEx HealthCare Logistics
6.3.7 ICON plc
6.3.8 IQVIA Supply Chain Services
6.3.9 KLIFO A/S
6.3.10 Lonza Group
6.3.11 Marken (UPS Healthcare)
6.3.12 Movianto (Yusen Logistics)
6.3.13 Myonex
6.3.14 N-SIDE
6.3.15 Parexel International
6.3.16 PCI Pharma Services
6.3.17 Piramal Pharma Solutions
6.3.18 Sharp Services LLC
6.3.19 Thermo Fisher Scientific (Patheon)
6.3.20 World Courier ( Cencora)
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment